BLPH — Bellerophon Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Bellerophon Reports Q1 Loss Per Share $1.08
Brief: Bellerophon Therapeutics Announces FDA Clears Initiation Of Phase 3 Study For Inopulse® Inhaled Nitric Oxide Therapy To Treat Covid-19
Brief: Bellerophon Submits Investigational New Drug Application To Study Inhaled Nitric Oxide Therapy For COVID-19
Brief: Bellerophon Therapeutics Q4 Loss Per Share $0.89
Brief: Bellerophon Therapeutics Says Unable To Complete The Required Financial Statements And Audit Required For Filing Its Annual Report On Form 10-K
Bellerophon: Pares gains on discounted stock offering
Brief: Bellerophon Therapeutics Announces First Patient Treated With Inopulse Inhaled Nitric Oxide Therapy For Covid-19
Bellerophon: Jumps after therapy used in first COVID-19 patient
Bellerophon skyrockets as FDA allows emergency use of therapy for coronavirus
NASDAQ RESUMED AT 04:04 PM
NASDAQ RESUMED AT 03:25 PM
NASDAQ RESUMED AT 03:01 PM
NASDAQ RESUMED AT 02:34 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 08:44 AM
Nasdaq Trade Halt Market Wide Circuit Breaker Halt: LEVEL 1 AT 08:42 AM
U.S. STOCKS ON THE MOVE-Apple, Intelsat, Tesla, Conagra
U.S. STOCKS ON THE MOVE-Legg Mason, Apple, Tesla, Fluor, Bellerophon Therapeutics
Bellerophon surges after positive data on blood pressure device
Brief: Bellerophon Reports Positive Top-Line Data From An Ancillary Acute Hemodynamic Study Of Inopulse